Molecular Diversity of Hydroxamic Acids: Part II. Potential Therapeutic Applications

被引：30

作者：

Lou, Boliang ^{[1
]}

Yang, Kexin ^{[1
]}

机构：

[1] Adv SynTech, Louisville, KY 40299 USA

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2003年 / 3卷 / 06期

关键词：

D O I：

10.2174/1389557033487872

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A hydroxamic acid moiety has been demonstrated as the key structural element in many highly potent and selective inhibitors against a variety of metalloprotease enzymes, such as MMPs, TACE, HDAC, PDF, etc. Over the last several years, there has been a rapid growth of literature and patent applications dealing with the development of the hydroxamic acid-based inhibitors. This review highlights the most recent examples to show their potential therapeutic applications.

引用

收藏

页码：609 / 620

页数：12

相关论文

共 94 条

[1]

ADANG AEP, 1994, RECL TRAV CHIM PAY B, V113, P63

[2] Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors [J].

Almstead, NG ;

Bradley, RS ;

Pikul, S ;

De, B ;

Natchus, MG ;

Taiwo, YO ;

Gu, F ;

Williams, LE ;

Hynd, BA ;

Janusz, MJ ;

Dunaway, CM ;

Mieling, GE .

JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (22) :4547-4562

[3] 2-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)- and 2-(2,2-dioxo-1,4-dihydro-2H-2λ6-benzo[1,2,6]thiadiazin-3-yl)-N-hydroxy-acetamides as potent and selective peptide deformylase inhibitors [J].

Apfel, C ;

Banner, DW ;

Bur, D ;

Dietz, M ;

Hubschwerlen, C ;

Locher, H ;

Marlin, F ;

Masciadri, R ;

Pirson, W ;

Stalder, H .

JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (12) :1847-1852

[4] Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents [J].

Apfel, C ;

Banner, DW ;

Bur, D ;

Dietz, M ;

Hirata, T ;

Hubschwerlen, C ;

Locher, H ;

Page, MGP ;

Pirson, W ;

Rossé, G ;

Specklin, JL .

JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (12) :2324-2331

[5] Peptide deformylase as an antibacterial drug target:: Assays for detection of its inhibition in Escherichia coli cell homogenates and intact cells [J].

Apfel, CM ;

Evers, S ;

Hubschwerlen, C ;

Pirson, W ;

Page, MGP ;

Keck, W .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1053-1057

[6] Peptide deformylase as an antibacterial drug target:: Target validation and resistance development [J].

Apfel, CM ;

Locher, H ;

Evers, S ;

Takács, B ;

Hubschwerlen, C ;

Pirson, W ;

Page, MGP ;

Keck, W .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1058-1064

[7] Aggrecanase - A target for the design of inhibitors of cartilage degradation [J].

Arner, EC ;

Pratta, MA ;

Decicco, CP ;

Xue, CB ;

Newton, RC ;

Trzaskos, JM ;

Magolda, RL ;

Tortorella, MD .

INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS, 1999, 878 :92-107

[8] Selective inhibition of low affinity IgE receptor (CD23) processing [J].

Bailey, S ;

Bolognese, B ;

Buckle, DR ;

Faller, A ;

Jackson, S ;

Louis-Flamberg, P ;

McCord, M ;

Mayer, RJ ;

Marshall, LA ;

Smith, DG .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (01) :29-34

[9] Hydroxamate-based inhibitors of low affinity IgE receptor (CD23) processing [J].

Bailey, S ;

Bolognese, B ;

Buckle, DR ;

Faller, A ;

Jackson, S ;

Louis-Flamberg, P ;

McCord, M ;

Mayer, RJ ;

Marshall, LA ;

Smith, DG .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (01) :23-28

[10] New α-substituted succinate-based hydroxamic acids as TNFα convertase inhibitors [J].

Barlaam, B ;

Bird, TG ;

Lambert-van der Brempt, C ;

Campbell, D ;

Foster, SJ ;

Maciewicz, R .

JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (23) :4890-4908

← 1 2 3 4 5 6 7 8 9 10 →